The fatal anemia is slightly accelerated by pretreatment of Apc^del/+recipients with ENU. (A) A model showing that Apc^fl/+and Apc^del/+ recipients (CD45.2⁺) were treated with pIpC at 2 months, ENU at 2.5 months (where indicated), and transplanted 4 weeks post-pIpC treatment with CD45.1/CD45.2 WT BM. (B) Kaplan-Meier survival curve of Apc^fl/+ (WT) or Apc^del/+ recipients transplanted with CD45.1/CD45.2 WT BM. Recipients treated with ENU are indicated (dashed line). (C) CBC of untreated and ENU-treated Apc^fl/+and Apc^del/+recipient mice. RBC, Hb, and MCV were significantly different for both untreated and ENU-treated Apc^del/+recipient mice compared with Apc^fl/+-recipient controls. Monocytosis was significant only for the ENU-treated Apc^del/+ vs Apc^fl/+-recipient mice. MO, monocytes.